Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0.5%, 0.1%, and 0.01% Doses (Atropine for the Treatment of Myopia 2)

被引:519
作者
Chia, Audrey [1 ,2 ]
Chua, Wei-Han [1 ,2 ]
Cheung, Yin-Bun [3 ,4 ]
Wong, Wan-Ling [2 ]
Lingham, Anushia [4 ]
Fong, Allan [1 ,2 ]
Tan, Donald [1 ,2 ,5 ]
机构
[1] Singapore Natl Eye Ctr, Singapore 168751, Singapore
[2] Singapore Eye Res Inst, Singapore, Singapore
[3] Duke NUS Grad Med Sch, Singapore, Singapore
[4] Singapore Clin Res Inst, Singapore, Singapore
[5] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore
基金
英国医学研究理事会;
关键词
CHILDREN; PROGRESSION; PREVENTION; PREVALENCE; GROWTH; ARREST; TRIAL;
D O I
10.1016/j.ophtha.2011.07.031
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: Our previous study, Atropine for the Treatment of Myopia 1 (ATOM1), showed that atropine 1% eyedrops were effective in controlling myopic progression but with visual side effects resulting from cycloplegia and mydriasis. The aim of this study was to compare efficacy and visual side effects of 3 lower doses of atropine: 0.5%, 0.1%, and 0.01%. Design: Single-center, double-masked, randomized study. Participants: A total of 400 children aged 6-12 years with myopia of at least -2.0 diopters (D) and astigmatism of -1.50 D or less. Intervention: Children were randomly assigned in a 2: 2: 1 ratio to 0.5%, 0.1%, and 0.01% atropine to be administered once nightly to both eyes for 2 years. Cycloplegic refraction, axial length, accommodation amplitude, pupil diameter, and visual acuity were noted at baseline, 2 weeks, and then every 4 months for 2 years. Main Outcome Measures: Myopia progression at 2 years. Changes were noted and differences between groups were compared using the Huber-White robust standard error to allow for data clustering of 2 eyes per person. Results: The mean myopia progression at 2 years was -0.30 +/- 0.60, -0.38 +/- 0.60, and -0.49 +/- 0.63 D in the atropine 0.5%, 0.1%, and 0.01% groups, respectively (P = 0.02 between the 0.01% and 0.5% groups; between other concentrations P > 0.05). In comparison, myopia progression in ATOM1 was -1.20 +/- 0.69 D in the placebo group and -0.28 +/- 0.92 D in the atropine 1% group. The mean increase in axial length was 0.27 +/- 0.25, 0.28 +/- 0.28, and 0.41 +/- 0.32 mm in the 0.5%, 0.1%, and 0.01% groups, respectively (P < 0.01 between the 0.01% and 0.1% groups and between the 0.01% and 0.5% groups). However, differences in myopia progression (0.19 D) and axial length change (0.14 mm) between groups were small and clinically insignificant. Atropine 0.01% had a negligible effect on accommodation and pupil size, and no effect on near visual acuity. Allergic conjunctivitis and dermatitis were the most common adverse effect noted, with 16 cases in the 0.1% and 0.5% atropine groups, and no cases in the 0.01% group. Conclusions: Atropine 0.01% has minimal side effects compared with atropine at 0.1% and 0.5%, and retains comparable efficacy in controlling myopia progression. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2012; 119: 347-354 (C) 2012 by the American Academy of Ophthalmology.
引用
收藏
页码:347 / 354
页数:8
相关论文
共 29 条
  • [1] BEDROSSIAN RH, 1979, OPHTHALMOLOGY, V86, P713
  • [2] BRENNER RL, 1985, ANN OPHTHALMOL, V17, P137
  • [3] BRODSTEIN RS, 1984, OPHTHALMOLOGY, V91, P1373
  • [4] Chiang M F, 2001, Binocul Vis Strabismus Q, V16, P209
  • [5] The effectiveness of 0.5% atropine in controlling high myopia in children
    Chou, AC
    Shih, YF
    Ho, TC
    Lin, LLK
    [J]. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 1997, 13 (01) : 61 - 67
  • [6] Atropine for the treatment of childhood myopia
    Chua, Wei-Han
    Balakrishnan, Vivian
    Chan, Yiong-Huak
    Tong, Louis
    Ling, Yvonne
    Quah, Boon-Long
    Tan, Donald
    [J]. OPHTHALMOLOGY, 2006, 113 (12) : 2285 - 2291
  • [7] Prevalence of Refractive Error in Singaporean Chinese Children: The Strabismus, Amblyopia, and Refractive Error in Young Singaporean Children (STARS) Study
    Dirani, Mohamed
    Chan, Yiong-Huak
    Gazzard, Gus
    Hornbeak, Dana Marie
    Leo, Seo-Wei
    Selvaraj, Prabakaran
    Zhou, Brendan
    Young, Terri L.
    Mitchell, Paul
    Varma, Rohit
    Wong, Tien Yin
    Saw, Seang-Mei
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (03) : 1348 - 1355
  • [8] Role of the non-neuronal cholinergic system in the eye: A review
    Duncan, G
    Collison, DJ
    [J]. LIFE SCIENCES, 2003, 72 (18-19) : 2013 - 2019
  • [9] Topical atropine in retarding myopic progression and axial length growth in children with moderate to severe myopia: A pilot study
    Fan, Dorothy S. P.
    Lam, Dennis S. C.
    Chan, Carmen K. M.
    Fan, Alex H.
    Cheung, Eva Y. Y.
    Rao, Srinivas K.
    [J]. JAPANESE JOURNAL OF OPHTHALMOLOGY, 2007, 51 (01) : 27 - 33
  • [10] Prevention of Myopia Onset with 0.025% Atropine in Premyopic Children
    Fang, Po-Chiung
    Chung, Mei-Yung
    Yu, Hun-Ju
    Wu, Pei-Chang
    [J]. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2010, 26 (04) : 341 - 345